The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy

Hematotoxicity is the most common long-term adverse event after chimeric antigen receptor T cell (CAR-T) therapy. Here, a total of 71 patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) or large B-cell lymphoma (LBCL) were used to develop an early hematotoxicity pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yang, Song, Zhiqiang, Geng, Yuke, Gao, Lei, Xu, Lili, Tang, Gusheng, Ni, Xiong, Chen, Li, Chen, Jie, Wang, Tao, Fu, Weijia, Feng, Dongge, Yu, Xuejun, Wang, Libing, Yang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561932/
https://www.ncbi.nlm.nih.gov/pubmed/36249041
http://dx.doi.org/10.3389/fonc.2022.987965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561932/
https://www.ncbi.nlm.nih.gov/pubmed/36249041
http://dx.doi.org/10.3389/fonc.2022.987965

Ejemplares similares